Therapy of tonsillopharyngitis: advantages of an integrated approach. A review

Cover Page

Cite item

Full Text

Abstract

The problem of pain in the pharynx continues to be the focus of attention of scientists and practitioners for many decades. Despite the emergence of modern methods of diagnosis and treatment, the problem of pharyngoalgia is far from being solved. It has now been established that more than 500 possible etiological factors can be the cause of pharyngoalgia, but the leading place is occupied by inflammatory diseases of the pharynx and palatine tonsils. Taking into account the wide distribution of this nosology among the population and the high risk of complications, especially in childhood, the issues related to the search for effective therapeutic regimens and ways to prevent the development of complications are still relevant. Definitely, the treatment should be safe, comprehensive, justified and individually selected in each case. Adequate therapy started in time allows avoiding the development of adverse effects, reducing the treatment time and improving the patient's quality of life. And for a doctor, it is extremely important to know the differences in the clinical picture of pharyngoalgia caused by different types of microorganisms: bacteria, viruses or fungal flora, since these differences will be decisive in the further tactics of treating the patient. This article is devoted to highlighting the issues of the complex use of the lysine salt of ketoprofen in local and systemic form. The parameters of the analgesic and anti-inflammatory action of the lysine salt of ketoprofen are characterized, and a new scheme for the treatment of inflammatory diseases of the pharynx within a single molecule is proposed. The article also pays attention to the prevention of complications and relapses, and discusses the advantages of the drug pidotimod in immunomodulatory therapy.

About the authors

Sergey V. Ryazantsev

Saint Petersburg Research Institute of Ear, Throat, Nose and Speech

Author for correspondence.
Email: professor.ryazantsev@mail.ru
ORCID iD: 0000-0003-1710-3092

D. Sci. (Med.), Prof., Saint Petersburg Research Institute of Ear, Throat, Nose and Speech

Russian Federation, Saint Petersburg

Galina S. Maltseva

Saint Petersburg Research Institute of Ear, Throat, Nose and Speech

Email: g.s.maltseva@gmail.com
ORCID iD: 0000-0003-0670-9566

D. Sci. (Med.), Saint Petersburg Research Institute of Ear, Throat, Nose and Speech

Russian Federation, Saint Petersburg

Svetlana S. Vysockaya

Saint Petersburg Research Institute of Ear, Throat, Nose and Speech

Email: s-ultraviolet@mail.ru
ORCID iD: 0000-0001-9976-3830

Deputy Head of the Department, Saint Petersburg Research Institute of Ear, Throat, Nose and Speech

Russian Federation, Saint Petersburg

References

  1. Карпова Е.П., Тулупов Д.А., Оборкин В.Ю. Симптом боли в горле в педиатрической практике. Учебное пособие. М.: ФГБОУ ДПО РМАНПО, 2019 [Karpova EP, Tulupov DA, Oborkin VIu. Simptom boli v gorle v pediatricheskoi praktike. Uchebnoe posobie. M.: FGBOU DPO RMANPO (in Russian)].
  2. Анготоева И.Б., Мушьян И.А. Боль в горле и ее причины. Российская оториноларингология. 2019;18(3):17-21 [Angotoeva IB, Mush’yan IA. Sore throat and its causes. Rossiiskaya otorinolaringologiya. 2019;18(3):17-21 (in Russian)]. doi: 10.18692/1810-4800-2019-3-17-21
  3. Овчинников А.Ю., Мирошниченко Н.А., Николаева Ю.О. Боль в горле. Современные подходы к лечению. Вестник оториноларингологии. 2020;85(4):35-9 [Ovchinnikov AYu, Miroshnichenko NA, Nikolaeva YuO. Sore throat. Recent trends in treatment. Vestn Otorinolaringol. 2020;85(4):35-9 (in Russian)]. doi: 10.17116/otorino20208504135
  4. Шахова Е.Г., Бакумова О.Р. Боль в горле: современные аспекты этиологии, диагностики и лечения. Фарматека. 2011;5:62-5 [Shakhova EG, Bakumova OR. Sore throat: modern aspects of etiology, diagnosis and treatment. Pharmateka. 2011;5:62-5 (in Russian)].
  5. Дроздова М.В., Преображенская Ю.С., Рязанцев С.В., Павлова С.С. Воспалительные заболевания глотки у детей. Медицинский совет. 2022;(1):51-7 [Drozdova MV, Preobrazhenskaya YuS, Ryazantsev SV, Pavlova SS. Inflammatory diseases of the pharynx in children. Meditsinskiy sovet = Medical Council. 2021;(1):51-7 (in Russian)]. doi: 10.21518/2079-701X-2022-16-1-51-57
  6. Нарбаев З.К., Сайдакбаров А.Ж. Этиология и патогенез хронического тонзиллита. Экономика и социум. 2022;2(93):784-7 [Narbaev ZK, Saidakbarov AZh. Etiology and pathogenesis of chronic tonsillitis. Economy and Society. 2022;2(93):784-7 (in Russian)].
  7. Анготоева И.Б., Магомедова М.М. Анализ микробиоты с поверхности небных миндалин у пациентов с ларингофарингеальным рефлюксом. Российская оториноларингология. 2022;21(2):8-15 [Angotoeva IB, Magomedova MM. Analysis of the microbiota from the surface of the tonsils in patients with laryngopharyngeal reflux. Rossiiskaya otorinolaringologiya. 2022;21(1):8-15 (in Russian)]. doi: 10.18692/1810-4800-2022-1-8-15
  8. Карпищенко С.А., Алексеенко С.И., Дроздова М.В., Баранская С.В. Возможности местной терапии боли в горле у детей. Медицинский совет. 2020;(18):72-9 [Karpishchenko SA, Alekseenko SI, Drozdova MV, Baranskaya SV. Local treatment options for sore throat in children. Meditsinskiy sovet = Medical Council. 2020;(18):72-9 (in Russian)]. doi: 10.21518/2079-701X-2020-18-72-79
  9. Дроздова М.В., Ларионова С.Н., Тырнова Е.В. Оценка роли микробиоты носоглотки в формировании хронического лимфопролиферативного синдрома ЛОР-органов у детей младшего возраста. Российская оториноларингология. 2022;21(5):19-26 [Drozdova MV, Larionova SN, Tyrnova EV. Evaluation of nasopharyngeal microbiota role in development of chronic lymphoproliferative syndrome of ENT organs in young children. Rossiiskaya otorinolaringologiya. 2022;21(5):19-26 (in Russian)]. doi: 10.18692/1810-4800-2022-5-19-26
  10. Рязанцев С.В., Каляпин Д.Д. Применение комбинированных препаратов нового поколения как компонент комплексной терапии воспалительных заболеваний глотки. Медицинский совет. 2018;(20):55-7 [Ryazantsev SV, Kalyapin DD. The next-generation combination drugs as part of the comprehensive therapy for inflammatory diseases of the pharynx. Meditsinskiy sovet = Medical Council. 2018;(20):55-7 (in Russian)]. doi: 10.21518/2079-701X-2018-20-55-57
  11. Свистушкин В.М., Никифорова Г.Н., Топоркова Л.А., Карпова О.Ю. Возможности топических этиотропных препаратов в лечении больных острым тонзиллофарингитом. РМЖ. 2018;10(II):97-102 [Svistushkin VM, Nikiforova GN, Toporkova LA, Karpova OYu. Possibilities of topical etiotropic drugs in the treatment of patients with acute tonsillopharyngitis. RMJ. 2018;10(II):97-102 (in Russian)].
  12. Клинические рекомендации (КР 306) Министерства здравоохранения Российской Федерации «Острый тонзиллит и фарингит (Острый тонзиллофарингит) 2021 г.» [Clinical recommendations (KR 306) of the Ministry of Health of the Russian Federation “Acute tonsillitis and pharyngitis (Acute tonsillopharyngitis) 2021” (in Russian)].
  13. Мальцева Г.С., Карпищенко С.А. Роль фитотерапии в лечении хронического тонзиллита. Медицинский совет. 2020;(6):36-43 [Maltseva GS, Karpishchenko SA. The role of herbal medicine in the treatment of chronic tonsillitis. Meditsinskiy sovet = Medical Council. 2020;(6):36-43 (in Russian)]. doi: 10.21518/2079-701X-2020-6-36-43
  14. Захарова И.Н., Геппе Н.А., Сугян Н.Г., и др. Топические этиотропные препараты в терапии инфекционно-воспалительных заболеваний глотки у детей дошкольного возраста. Результаты многоцентрового рандомизированного клинического исследования. Российская оториноларингология. 2021;20(1):102-17 [Zakharova IN, Geppe NA, Sugyan NG, et al. Topical etiotropic drugs in therapy of infectious inflammatory diseases of pharynx in preschool children. Results of multicenter randomized comparative clinical trial. Rossiiskaya otorinolaringologiya. 2021;20(1):102-17 (in Russian)]. doi: 10.18692/1810-4800-2021-1-102-117
  15. Гуров А.В., Мужичкова А.В., Юшкина М.А. Комплексный подход к лечению воспалительных заболеваний верхних дыхательных путей. Лечебное дело. 2021;3:23-8 [Gurov AV, Muzhichkova AV, Yushkina MA. An Integrated Approach to Treatment of Inflammatory Diseases of the Upper Respiratory Tract. General Medicine. 2021;3:23-8 (in Russian)]. doi: 10.24412/2071-5315-2021-12356
  16. Морозова С.В., Щенникова Е.С. Выбор эффективной терапии при инфекционно-воспалительных заболеваниях глотки. Consilium Medicum. 2020;22(11):21-4 [Morozova SV, Shchennikova ES. The choice of effective treatment for infectious and inflammatory diseases of the pharynx. Consilium Medicum. 2020;22(11):21-4 (in Russian)]. doi: 10.26442/20751753.2020.11.200411
  17. Natale F, de'Lorenzi C. The efficacy of and tolerance for ketoprofen lysine salt in solution for oropharyngeal use in inflammatory lesions of the oral cavity. Stomatol de Minerve. 1997;46(5):273-8.
  18. Lauritano D, Spadari F, Salvato A. Efficacy of and tolerance to topical ketoprofen lysinate solution in acute inflammation of the mouth in orthodontic therapy. Randomized single blind study, with parallel groups, versus benzidamine hydrochloride. Minerva Stomatol. 2000;49(11-12):561-8.
  19. Passali D, Volonte M, Passali GC, et al. Efficacy and safety of ketoprofen lysine salt mouthwash versus benzydamine hydrochloride mouthwash in acute pharyngeal inflammation: a randomized, single-blind study. Clin Ther. 2001;23(9):1508-18. doi: 10.1016/s0149-2918(01)80123-5
  20. Карпова Е.П., Тулупов Д.А., Федотов Ф.А. Использование нестероидных противовоспалительных средств для купирования болевого синдрома после тонзиллотомии у детей. Вестник оториноларингологии. 2017;82(5):48-51 [Karpova EP, Tulupov DA, Fedotov FA. The application of different non-steroidal anti-inflammatory drugs for the elimination of pain syndrome during the early postoperative period in the children following the surgical interventions on palatine tonsils. Vestn Otorinolaringol. 2017;82(5):48-51 (in Russian)]. doi: 10.17116/otorino201782548-51
  21. Sarzi-Puttini P, Atzeni F, Lanata L. Pain and ketoprofen: what is its role in clinical practice? Reumatismo. 2010;62(3):172-88.
  22. Matsumo S, Kaneda K, Norhara Y. Clinical evaluation of ketoprofen (Orudis) in lumbago – a double-blind comparison with diclofenac sodium. Br J Clin Pract. 1981;35(7-8):266.
  23. Bellussi L, Biagini C. Antiphlogistic therapy with ketoprofen lysine salt vs nimesulide in secretoty otitis media, rhinitis/rhinosinusitis, pharyngitis/tonsillitis/tracheitis. Note di Terapia Otorinolaringol. 1996;46:49-57.
  24. Panerai AE, Lanata L, Ferrari M, Bagnasco M. A New ketoprofen lysine salt formulation: 40 mg orodispersible granules. Trends Med. 2012;12(4):159-67.
  25. Barden J, Derry S, McQuay HJ, Moore RA. Single dose oral ketoprofen and dexketoprofen for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009;(4):CD007355. doi: 10.1002/14651858.CD007355.pub2
  26. Харламовa Ф., Учайкин В., Кладова О., Бевза С. Применение препарата пидотимод при острой респираторной инфекции у часто болеющих детей. Вопросы современной педиатрии. 2009;8(2):27-33 [Kharlamova FS, Uchaikin VF, Kladova OV, Bevza SL. Pathogenetic Substantiation of Imunoriks Usage in the Case of Acute Respiratory Virus Infections (ARVI) in Sickly Children. Current Pediatrics. 2008;8(2):27-33 (in Russian)].
  27. Зайцева С.В., Зайцева О.В. Острые респираторные инфекции у детей: этиопатогенетические возможности современной терапии. Медицинский совет. 2014;(5):22-30 [Zaytseva SV, Zaytseva OV. Acute respiratory infections in children: etрiopathogenetic possibilities of modern therapy. Meditsinskiy sovet = Medical Council. 2014;(5):22-30 (in Russian)]. doi: 10.21518/2079-701X-2014-6-22-30
  28. Zhao N, Liu C, Zhu C, et al. Рidotimod: a review of its pharmacological features and clinical effectiveness in respiratory tract infections. Expert Rev Anti Infect Ther. 2019;17(10):803-18. doi: 10.1080/14787210.2019.1679118
  29. Capsoni F, Minonzio F, Ongari AM, et al. Evaluation of the kinetics of the immunomodulating activity of Pidotimod on human neutrophils. Pharmacol Res. 1992;26(2):172-3. doi: 10.1016/1043-6618(92)90650-z
  30. Coppi G, Manzandro S. Experimental immunological screening tests on pidotimod. Arzneimittel Forschung. 1994;44(12A):1411-6.
  31. Coppi G, Falcone А, Manzandro S. Protective effects of pidotimod against bacterial infectionsin mice. Arzneimittel Forschung. 1994;44(12A):1417-21.
  32. Taramelli D, Malabarba MG, Basilico N, et al. Effects of Pidotimod on macrophage functions in methylprednisolone-treated mice. Arzneimittel Forschung. 1994;44:1425-30.
  33. Migliorati G, D'Adamio L, Coppi G, et al. Pidotimod stimulates natural killers and inhibits thymocyte cell death. Immunopharmacol Immunotoxicol. 1992;14:737-48. doi: 10.3109/08923979209009231
  34. Hu X, Zhang W, Wang L, et al. The detailed analysis of the changes of murine dendritic cells (DCs) induced by thymic peptide: pidotimod (PTD). Hum Vaccin Immunother. 2012;8(9):1250-8. doi: 10.4161/hv.20579
  35. Zuccotti GV, Mameli C, Trabattoni D, et al. Immunomodulating activity of Pidotimod in children with Down syndrome. J Biol Regul Homeost Agents. 2013;27(1):253-8.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Etiological agents of pharyngealgia.

Download (173KB)
Indexing metadata

Copyright (c) 2023 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies